Personalized approach to the management of a patient with COVID-19 with a complicated comorbid background
Q4 Social Sciences
S. Chepurnenko, G. Shavkuta, N. M. Bulgakova, A. V. Safonova
{"title":"Personalized approach to the management of a patient with COVID-19 with a complicated comorbid background","authors":"S. Chepurnenko, G. Shavkuta, N. M. Bulgakova, A. V. Safonova","doi":"10.33029/2305-3496-2023-12-1-116-122","DOIUrl":null,"url":null,"abstract":"The aim of the work is to form the principles of a personalized approach to the management of patients with COVID-19 with a complicated comorbid background. Material and methods. The article describes a clinical case of successful recovery of an 87-year-old patient from a new coronavirus infection COVID-19, complicated by pneumonia involving 36% of the lung parenchyma area. Along with age, the situation was aggravated by the comorbid status of the patient: the presence of chronic lymphocytic leukemia, hypertension, mechanical prostheses of the mitral and aortic valves, postinfarction cardiosclerosis, paroxysmal atrial fibrillation, type 2 diabetes mellitus, stage 4 CKD, anemic syndrome, and subclinical hypothyroidism. Results. The C-reactive protein level at admission was 114.46 mg/L. The patient refused hospitalization. Baricitinib 4 mg, favipiravir according to the scheme, vitamin D 2000 units were prescribed for the previously taken therapy. Already after 3 days, C-reactive protein decreased by 4.6 times, and by the 8th day by 15.5 times and amounted to 7.38 mg/ml. The temperature returned to normal on day 2 from the start of baricitinib. In dynamics, a decrease in creatinine level to 177.0 mumol/l was noted, the glomerular filtration rate increased to 30 ml/min/1.73 m2, which corresponded to stage 3b of CKD (a pronounced decrease in glomerular filtration rate). Conclusion. Despite the age of the patient, many comorbidities, each of which could be fatal, the timely use of baricitinib on an outpatient basis made it possible to stop the progressive course of the disease.Copyright © Eco-Vector, 2023. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases: News, Opinions, Training","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33029/2305-3496-2023-12-1-116-122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Social Sciences","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the work is to form the principles of a personalized approach to the management of patients with COVID-19 with a complicated comorbid background. Material and methods. The article describes a clinical case of successful recovery of an 87-year-old patient from a new coronavirus infection COVID-19, complicated by pneumonia involving 36% of the lung parenchyma area. Along with age, the situation was aggravated by the comorbid status of the patient: the presence of chronic lymphocytic leukemia, hypertension, mechanical prostheses of the mitral and aortic valves, postinfarction cardiosclerosis, paroxysmal atrial fibrillation, type 2 diabetes mellitus, stage 4 CKD, anemic syndrome, and subclinical hypothyroidism. Results. The C-reactive protein level at admission was 114.46 mg/L. The patient refused hospitalization. Baricitinib 4 mg, favipiravir according to the scheme, vitamin D 2000 units were prescribed for the previously taken therapy. Already after 3 days, C-reactive protein decreased by 4.6 times, and by the 8th day by 15.5 times and amounted to 7.38 mg/ml. The temperature returned to normal on day 2 from the start of baricitinib. In dynamics, a decrease in creatinine level to 177.0 mumol/l was noted, the glomerular filtration rate increased to 30 ml/min/1.73 m2, which corresponded to stage 3b of CKD (a pronounced decrease in glomerular filtration rate). Conclusion. Despite the age of the patient, many comorbidities, each of which could be fatal, the timely use of baricitinib on an outpatient basis made it possible to stop the progressive course of the disease.Copyright © Eco-Vector, 2023. All rights reserved.
具有复杂合并症背景的COVID-19患者的个性化治疗方法
这项工作的目的是形成具有复杂合并症背景的COVID-19患者个性化管理方法的原则。材料和方法。本文描述了一名87岁的新型冠状病毒感染COVID-19患者成功康复的临床病例,并合并肺实质面积36%的肺炎。随着年龄的增长,患者的合并症加重了这种情况:慢性淋巴细胞白血病、高血压、二尖瓣和主动脉瓣机械假体、梗死后心脏硬化、阵发性心房颤动、2型糖尿病、4期CKD、贫血综合征和亚临床甲状腺功能减退。结果。入院时c反应蛋白水平为114.46 mg/L。病人拒绝住院治疗。Baricitinib 4mg, favipiravir根据方案,维生素D 2000单位为先前采取的治疗处方。3天后,c反应蛋白下降了4.6倍,到第8天下降了15.5倍,达到7.38 mg/ml。开始使用巴西替尼后第2天体温恢复正常。在动力学上,肌酐水平下降到177.0 mumol/l,肾小球滤过率增加到30 ml/min/1.73 m2,这与CKD 3b期相对应(肾小球滤过率明显下降)。结论。尽管患者年龄大,有许多合并症,每一种合并症都可能致命,但在门诊及时使用巴西替尼可以阻止疾病的进展过程。版权所有©Eco-Vector, 2023。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。